DHG Pharmaceutical JSC (DHG) - Total Liabilities

Latest as of December 2025: ₫983.26 Billion VND ≈ $37.36 Million USD

Based on the latest financial reports, DHG Pharmaceutical JSC (DHG) has total liabilities worth ₫983.26 Billion VND (≈ $37.36 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore DHG Pharmaceutical JSC cash flow conversion to assess how effectively this company generates cash.

DHG Pharmaceutical JSC - Total Liabilities Trend (2019–2025)

This chart illustrates how DHG Pharmaceutical JSC's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of DHG Pharmaceutical JSC to evaluate the company's liquid asset resilience ratio.

DHG Pharmaceutical JSC Competitors by Total Liabilities

The table below lists competitors of DHG Pharmaceutical JSC ranked by their total liabilities.

Company Country Total Liabilities
Compagnie du Bois Sauvage SA
BR:COMB
Belgium €186.49 Million
BlackRock Core Bond Closed Fund
NYSE:BHK
USA $346.00 Million
Anhui Shiny Electronic Technology Company Limited
SHE:300956
China CN¥1.82 Billion
BlackRock Limited Duration Income Trust
NYSE:BLW
USA $308.21 Million
Issta Lines Ltd
TA:ISTA
Israel ILA2.29 Billion
Hubei Fuxing Science and Technology Co Ltd
SHE:000926
China CN¥18.35 Billion
ValueHD Corp. A
SHE:301318
China CN¥165.33 Million
Picpay Holdings Netherlands N.V. Class A Common Shares
NASDAQ:PICS
USA $34.71 Billion

Liability Composition Analysis (2019–2025)

This chart breaks down DHG Pharmaceutical JSC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see DHG market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.29 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.24 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.19 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how DHG Pharmaceutical JSC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for DHG Pharmaceutical JSC (2019–2025)

The table below shows the annual total liabilities of DHG Pharmaceutical JSC from 2019 to 2025.

Year Total Liabilities Change
2025-12-31 ₫983.26 Billion
≈ $37.36 Million
-47.26%
2024-12-31 ₫1.86 Trillion
≈ $70.84 Million
+48.26%
2023-12-31 ₫1.26 Trillion
≈ $47.78 Million
+43.45%
2022-12-31 ₫876.65 Billion
≈ $33.31 Million
+6.32%
2021-12-31 ₫824.52 Billion
≈ $31.33 Million
-6.25%
2020-12-31 ₫879.46 Billion
≈ $33.41 Million
+14.32%
2019-12-31 ₫769.27 Billion
≈ $29.23 Million
--

About DHG Pharmaceutical JSC

VN:DHG Vietnam Drug Manufacturers - Specialty & Generic
Market Cap
$496.76 Million
₫13.07 Trillion VND
Market Cap Rank
#12579 Global
#62 in Vietnam
Share Price
₫100000.00
Change (1 day)
+0.30%
52-Week Range
₫97700.00 - ₫109000.00
All Time High
₫130801.51
About

DHG Pharmaceutical Joint Stock Company, together with its subsidiaries, engages in the manufacture and sale of pharmaceutical products in Vietnam. The company offers antibiotic, analgesic and antipyretic, respiratory, nutrition, musculoskeletal, gastrointestinal and hepatobiliary, nervous and ophthalmic, cardiovascular and diabetic, and dermatology and beauty care products. It also manufactures a… Read more